CN1861112A - Application of Qishen Yiqi dripping pills for preparing medicine to inhibit leakage of albumin - Google Patents
Application of Qishen Yiqi dripping pills for preparing medicine to inhibit leakage of albumin Download PDFInfo
- Publication number
- CN1861112A CN1861112A CN 200510013504 CN200510013504A CN1861112A CN 1861112 A CN1861112 A CN 1861112A CN 200510013504 CN200510013504 CN 200510013504 CN 200510013504 A CN200510013504 A CN 200510013504A CN 1861112 A CN1861112 A CN 1861112A
- Authority
- CN
- China
- Prior art keywords
- albumin
- qishen yiqi
- radix
- salviae miltiorrhizae
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 37
- 108010088751 Albumins Proteins 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 239000006187 pill Substances 0.000 title abstract description 4
- 239000008412 qishen yiqi Substances 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 25
- 210000003462 vein Anatomy 0.000 claims description 25
- 239000009636 Huang Qi Substances 0.000 claims description 19
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 19
- 241000180649 Panax notoginseng Species 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000003405 preventing effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 description 27
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 210000000713 mesentery Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000004731 jugular vein Anatomy 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 244000132619 red sage Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An application of the 'Qi-replenishing' Qishen dripping pill in preparing the medicines for preventing and treating the microcirculatory disturbance diseases caused by albumin leakage is disclosed.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to QISHEN YIQI DIWAN application in the albumin outside leakage medicine in preparation suppresses thin vein.
Background technology
The microcirculation disturbance that Radix Salviae Miltiorrhizae causes ischemia-reperfusion has prevention and therapeutical effect.Its mechanism of action comprises the protection vascular endothelial cell, remove peroxide, suppress leukocyte adheres to, suppresses mast cell degranulation, suppresses that the interior albumin of thin vein spills etc. with blood vessel endothelium.Radix Salviae Miltiorrhizae has been brought into play the microcirculation disturbance effect that its prevention and treatment ischemia-reperfusion cause by to microcirculatory too many levels, the comprehensive function of many target spots.Yet in the prevention of cardiovascular and cerebrovascular disease with when needing long-term treatment, Radix Salviae Miltiorrhizae needs intravenously administrable to be subjected to the restriction of each side factor.If oral red sage formulation also can be obtained and the intravenously administrable propinquity effect, will be very significant for prevention and treatment cardiovascular and cerebrovascular disease or other diseases with microcirculatory disturbances.
QISHEN YIQI DIWAN is made up of the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng and Lignum Dalbergiae Odoriferae, in order to the angina pectoris of treatment coronary heart disease with qi deficiency and blood stasis.Chinese patent CN1375316A discloses composition, method for making and the purposes aspect angina pectoris of said preparation, but this medicine albumin outside leakage and effect aspect the microcirculation improvement in anti-thin vein do not appear in the newspapers as yet.
Summary of the invention
The purpose of this invention is to provide QISHEN YIQI DIWAN application in the albumin outside leakage medicine in preparation suppresses thin vein.
The present invention by FITC (fluorescein) sign albumin outside leakage in the rat mesentery thin vein that ischemia-reperfusion is caused dynamically, seriality, visual observation, albuminous leaking outside all has inhibitory action significantly to visible QISHEN YIQI DIWAN oral administration early stage and late period to rat mesentery thin vein ischemia-reperfusion.
QISHEN YIQI DIWAN is to be prepared from by following component by weight percentage: the Radix Astragali 22.2%～66.8%, Radix Salviae Miltiorrhizae 11.6%～33.4%, Radix Notoginseng 2.5%～13.5%, Lignum Dalbergiae Odoriferae 14.5%～44.3%.Its best proportioning is the Radix Astragali 44.7%, Radix Salviae Miltiorrhizae 26.7%, Radix Notoginseng 6.3%, Lignum Dalbergiae Odoriferae 22.3%; Perhaps with the Radix Astragali 41.2%, Radix Salviae Miltiorrhizae 23.8%, Radix Notoginseng 4.5%, Lignum Dalbergiae Odoriferae 30.5%.
For a better understanding of the present invention, below by experiment its new purposes in pharmaceutical field is described.
One, QISHEN YIQI DIWAN before ischemia-reperfusion administration to the inhibitory action of albumin outside leakage in the rat mesentery thin vein
(1) experimental technique
1. test group and matched group
(1) normal control group: do not carry out ischemia-reperfusion and handle.
(2) ischemia-reperfusion group: after 10 minutes bases are observed, will also flow mesentery artery and vein vascular ligation 10 minutes (ischemia) simultaneously, and remove ligation (pouring into again) in observation portion with 4G polyethylene pipe.Time recorder is transferred to 0 place.Observed 30 minutes continuously at the same visual field.
(3) QISHEN YIQI DIWAN administration group: before 60 minutes, press the dosage of 0.4g/kg at ischemia-reperfusion, with the QISHEN YIQI DIWAN physiological saline solution, disposable filling stomach.
(4) Radix Salviae Miltiorrhizae intravenously administrable group: at ischemia-reperfusion before 10 minutes, slowly inject Radix Salviae Miltiorrhizae Injection 1ml (1g Radix Salviae Miltiorrhizae extract/ml) through jugular vein, the continuous injector of reuse is pressed the per hour dosage of 1.2g/kg, injects Danshen root injection continuously through jugular vein and finishes to observing.
2. experimental technique
Get the Wistar male rat (body weight 200～250g, Charles River laboratory animal, Tokyo) that Japan's celebrating answers university of private school charging no tuition medical board Experimental Animal Center to raise, anaesthetize by the dosage lumbar injection pentobarbital sodium of 30mg/kg.Insert and put the 3G polyethylene tube from right external jugular vein.Make 2～3cm otch along the abdomen median line, gently the ileum of nearly ileocecus is moved to outside the abdominal cavity, mesentery is launched on the platen with thin slide.Be holding temperature and humidity, continue the Krebs-Ringer buffer of 37 ℃ of droppings on unfolded mesenteric mesaraic surface.Mesentery is microcirculatory dynamically, with inverted biological microscope (Diaphot TMD-2S, Nikon, the Tokyo) observation that places in 37 ℃ of temperature chambers, and uses the high sensitivity camera photography, the S-VHS video-recorder recording.
Select diameter to be look-out station at the non-branching portion of thin vein between 25～40 μ m (more than the long 200 μ m).After 10 minutes bases are observed, with of the mesentery artery and vein vascular simultaneously ligation 10 minute (ischemia) of 4G polyethylene tube, remove ligation (perfusion again) with observation portion, time recorder is transferred to 0 place.Observed 30 minutes continuously at the same visual field.
3. assay method
Thin vein vascular permeability assay: the fluorescein-labeled albumin of FITC is pressed the dosage of 50mg, slowly inject through jugular vein.With fluorescence microscopy camera chain (C-2400-08, creek pine), be 420～490nm at wavelength, emission wavelength is that the fluorescence excitation element is luminous under the condition of 520nm, observes and write down the variation of the inside and outside FITC fluorescein of same thin vein.Change according to the FITC fluorescein that in the thin vein pipe, outside the thin vein pipe, spills, through the time calculate the albuminous situation that spills, with the variation of expression thin vein vascular permeability.
Each measured value of every group of 6 rats is handled with one-way analysis of variance (ANOVA), Fisher ' s posthoc test check.Each is organized numerical value and represents that with average ± standard error establishing P＜0.05 is significance.
(2) result
Fig. 1 shows the influence that rat mesentery thin vein FITC tagged albumin leaks outside after QISHEN YIQI DIWAN and Radix Salviae Miltiorrhizae intravenously administrable are to ischemia-reperfusion.When perfusion began again, leaking outside of the thin vein FITC tagged albumin of ischemia-reperfusion group compared remarkable increase with the normal control group.Along with dabbling carrying out again, the leaking outside of FITC tagged albumin of ischemia-reperfusion group continues to increase.The albumin outside leakage of perfusion early stage (pouring into again within 10 minutes) when the Radix Salviae Miltiorrhizae intravenously administrable fails to suppress perfusion beginning again and again, but compare significantly with ischemia-reperfusion group and to reduce pouring into late period leaking outside of (pouring into again 20 minutes and 30 minutes) Radix Salviae Miltiorrhizae intravenously administrable group FITC tagged albumin again.The QISHEN YIQI DIWAN group early stage just suppressed the FITC tagged albumin significantly and has leaked outside dabbling again, and in dabbling late period again, its effect that suppresses albumin outside leakage is identical with the Radix Salviae Miltiorrhizae intravenously administrable.
Two, QISHEN YIQI DIWAN behind ischemia-reperfusion administration to the inhibitory action of albumin outside leakage in the rat mesentery thin vein
(1) experimental technique
1. test group and matched group
(1) normal control group: do not carry out ischemia-reperfusion and handle.
(2) QISHEN YIQI DIWAN administration group: behind ischemia-reperfusion, QISHEN YIQI DIWAN is made into the solution of 50mg/ml with normal saline, drips (2.6ml/min) continuously on the mesentery surface of observing.
(3) SOD (superoxide dismutase) administration group: in the time of 10 minutes,, inject SOD continuously through jugular vein and finish to observing with the dosage that continuous injector is pressed 12000u/kg/hr at ischemia-reperfusion.
2. experimental technique: with embodiment one.
3. assay method: with embodiment one.
(2) result
Fig. 2 shows that ischemia-reperfusion adds the influence that QISHEN YIQI DIWAN and SOD leak outside to rat mesentery thin vein FITC tagged albumin after 10 minutes.When pouring into 10 minutes again (QISHEN YIQI DIWAN drop into SOD before), the spilling of the FITC tagged albumin of administration group behind administration group, the SOD after ischemia-reperfusion group, the QISHEN YIQI DIWAN all significantly more than the normal control group.The medicine group is when dropping into continuously SOD 20 minutes (pouring into again 30 minutes) behind the SOD, and leaking outside of FITC tagged albumin do not improved in the thin vein.Administration group after the QISHEN YIQI DIWAN when dropping into 20 minutes (pouring into 30 minutes) continuously, has been improved leaking outside of thin vein FITC tagged albumin significantly again.The outer leak rate of the FITC tagged albumin of administration group not only is markedly inferior to ischemia-reperfusion group after the QISHEN YIQI DIWAN, also is markedly inferior to administration group behind the SOD.Leaking outside of the rat mesentery thin vein FITC tagged albumin that administration causes ischemia-reperfusion behind the SOD do not have therapeutical effect in during this observation, and administration has therapeutical effect after the QISHEN YIQI DIWAN.
Peroxide injured blood vessel endothelium and blood vessel basement membrane that ischemia-reperfusion produces impel albumin outside leakage.The vaso-active substance that mast cell degranulation discharges has more aggravated albumin outside leakage.Albumin outside leakage and mast cell degranulation are one of important symbols of microcirculation disturbance.The present invention proves that QISHEN YIQI DIWAN not only has the effect that suppresses albumin outside leakage, and its inhibition albumin outside leakage acts on again, and perfusion is better than the Radix Salviae Miltiorrhizae intravenously administrable in early days.QISHEN YIQI DIWAN is with Radix Salviae Miltiorrhizae and Radix Notoginseng and the Radix Astragali, Lignum Dalbergiae Odoriferae compatibility, and its effect of safeguarding vascular permeability has obtained reinforcement, and the early stage albumin outside leakage of ischemia that independent use can not play a role to Radix Salviae Miltiorrhizae also has inhibitory action.
Description of drawings
Fig. 1: the pre-administration of QISHEN YIQI DIWAN to ischemia-reperfusion after the influence that leaks outside of rat mesentery thin vein FITC tagged albumin.
Fig. 2: after the QISHEN YIQI DIWAN administration to ischemia-reperfusion after the influence that leaks outside of rat mesentery thin vein FITC tagged albumin.
The specific embodiment
Below in conjunction with embodiment medicine of the present invention is described further, following each embodiment only is used to the present invention is described and is not limitation of the present invention.
Embodiment one
Get Radix Astragali 86.5g, Radix Salviae Miltiorrhizae 21.3g, Radix Notoginseng 3.5g, Lignum Dalbergiae Odoriferae 20.6g, adjuvant Polyethylene Glycol-6000 30g.Will be through Radix Salviae Miltiorrhizae, the Radix Notoginseng of pulverizing, decocting boils 2 times, adds 7 times of water gagings at every turn, each 2 hours, merge decoction liquor, filter, filtrate is concentrated into 900ml, add 95% ethanol, make determining alcohol reach 70%, left standstill 12～24 hours, filter, reclaim ethanol, being condensed into relative density is the extractum of 1.32～1.38 (50～60 ℃); To decoct with water 2 times through the Radix Astragali of pulverizing, add 6 times of water gagings at every turn, extracted successively 2 hours, 1 hour, merging filtrate is when being concentrated into the 1500ml left and right sides, adding 95% ethanol, to make determining alcohol be 60%, left standstill 12～24 hours, filters, filtrate recycling ethanol, when being concentrated into the 400ml left and right sides, adding 95% ethanol, to make determining alcohol be 80%, left standstill 12～24 hours, filter, filtrate recycling ethanol, being condensed into relative density is the extractum of 1.32～1.38 (50～60 ℃); Get Lignum Dalbergiae Odoriferae, add 5 times of water gagings, reflux, extract, 5 hours is collected volatile oil; Get above-mentioned Salvia miltiorrhiza and Panax notoginseng extractum, Radix Astragali extractum and Polyethylene Glycol-6000, water-bath is dissolved, and after change is even, adds volatile oil of Lignum Dalbergiae Odoriferae, and mixing moves in the drop pill machine, makes 1000 drop pill.
Embodiment two
Get Radix Astragali 40.6g, Radix Salviae Miltiorrhizae 44.8g, Radix Notoginseng 11.2g, Lignum Dalbergiae Odoriferae 38.6g, adjuvant Polyethylene Glycol-6000 30g makes Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment three
Get Radix Astragali 77.3g, Radix Salviae Miltiorrhizae 22.8g, Radix Notoginseng 4.8g, Lignum Dalbergiae Odoriferae 30.5g, adjuvant Polyethylene Glycol-6000 28g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment four
Get Radix Astragali 42.3g, Radix Salviae Miltiorrhizae 39.2g, Radix Notoginseng 8.2g, Lignum Dalbergiae Odoriferae 46.8g, adjuvant Polyethylene Glycol-6000 25g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment five
Get Radix Astragali 65.2g, Radix Salviae Miltiorrhizae 38.9g, Radix Notoginseng 9.3g, Lignum Dalbergiae Odoriferae 32.5g, adjuvant Polyethylene Glycol-6000 40g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment six
Get Radix Astragali 56.2g, Radix Salviae Miltiorrhizae 32.5g, Radix Notoginseng 6.2g, Lignum Dalbergiae Odoriferae 41.6g, adjuvant Polyethylene Glycol-6000 22g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment seven
Get Radix Astragali 36.5g, Radix Salviae Miltiorrhizae 32.4g, Radix Notoginseng 6.2g, Lignum Dalbergiae Odoriferae 41.7g, adjuvant Polyethylene Glycol-6000 22g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment eight
Get Radix Astragali 65.6g, Radix Salviae Miltiorrhizae 25.8g, Radix Notoginseng 9.5g, Lignum Dalbergiae Odoriferae 46.4g, adjuvant Polyethylene Glycol-6000 35g makes Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Embodiment nine
Get Radix Astragali 35.5g, Radix Salviae Miltiorrhizae 50.8g, Radix Notoginseng 16.3g, Lignum Dalbergiae Odoriferae 52.3g, adjuvant Polyethylene Glycol-6000 35g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.
Claims (5)
1. the application of QISHEN YIQI DIWAN in preparation inhibition albumin outside leakage medicine.
2. QISHEN YIQI DIWAN application in the albumin outside leakage medicine in preparation suppresses thin vein.
3. the application of QISHEN YIQI DIWAN according to claim 1 and 2 in preparation inhibition albumin outside leakage medicine, it is characterized in that, described QISHEN YIQI DIWAN is to be prepared from by following component by weight percentage: the Radix Astragali 22.2%～66.8%, Radix Salviae Miltiorrhizae 11.6%～33.4%, Radix Notoginseng 2.5%～13.5%, Lignum Dalbergiae Odoriferae 14.5%～44.3%.
4. the application of QISHEN YIQI DIWAN according to claim 3 in preparation inhibition albumin outside leakage medicine, it is characterized in that described QISHEN YIQI DIWAN is to be prepared from by following component by weight percentage: the Radix Astragali 44.7%, Radix Salviae Miltiorrhizae 26.7%, Radix Notoginseng 6.3%, Lignum Dalbergiae Odoriferae 22.3%.
5. the application of QISHEN YIQI DIWAN according to claim 3 in preparation inhibition albumin outside leakage medicine, it is characterized in that described QISHEN YIQI DIWAN is to be prepared from by following component by weight percentage: the Radix Astragali 41.2%, Radix Salviae Miltiorrhizae 23.8%, Radix Notoginseng 4.5%, Lignum Dalbergiae Odoriferae 30.5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100135048A CN1861112B (en) | 2005-05-13 | 2005-05-13 | Application of Qishen Yiqi dripping pills for preparing medicine to inhibit leakage of albumin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100135048A CN1861112B (en) | 2005-05-13 | 2005-05-13 | Application of Qishen Yiqi dripping pills for preparing medicine to inhibit leakage of albumin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1861112A true CN1861112A (en) | 2006-11-15 |
| CN1861112B CN1861112B (en) | 2011-11-30 |
Family
ID=37388698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100135048A Active CN1861112B (en) | 2005-05-13 | 2005-05-13 | Application of Qishen Yiqi dripping pills for preparing medicine to inhibit leakage of albumin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1861112B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103385920A (en) * | 2012-05-07 | 2013-11-13 | 天士力制药集团股份有限公司 | Novel application of qi-tonifying dropping pill containing Radix astragali and root of red-rooted salvia |
| CN103520270A (en) * | 2012-07-02 | 2014-01-22 | 天士力制药集团股份有限公司 | Application of astragalus-salviae miltiorrhizae qi-benefiting dropping pills in resistance to anti-cancer medicine cardiotoxicity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1248702C (en) * | 2002-02-07 | 2006-04-05 | 天津天士力制药股份有限公司 | Traditional Chinese medicine preparation for treating coronary heart disease angina pectoris and preparation method thereof |
-
2005
- 2005-05-13 CN CN2005100135048A patent/CN1861112B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103385920A (en) * | 2012-05-07 | 2013-11-13 | 天士力制药集团股份有限公司 | Novel application of qi-tonifying dropping pill containing Radix astragali and root of red-rooted salvia |
| CN103520270A (en) * | 2012-07-02 | 2014-01-22 | 天士力制药集团股份有限公司 | Application of astragalus-salviae miltiorrhizae qi-benefiting dropping pills in resistance to anti-cancer medicine cardiotoxicity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1861112B (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9161959B2 (en) | Use of a vegetable drug composition in the manufacturing of pharmaceutical preparation for the treatment of portal hypertension caused by hepatocirrhosis | |
| CN1861112A (en) | Application of Qishen Yiqi dripping pills for preparing medicine to inhibit leakage of albumin | |
| CN101040906A (en) | Injection for treating cardiovascular or cerebrovascular disease and the preparing method and the quality control method | |
| CN1172677C (en) | Application of astragaloside IV in preparation of pharmaceutical composition | |
| CN100500669C (en) | A kind of salvianolic acid berberine double salt and its preparation method and application | |
| CN101623437B (en) | Pulse-activating preparation for injection and preparation method thereof | |
| CN1480195A (en) | Formula of Chinese herbal medicine of injection and bougie for treating kidney failure as well as its preparing method | |
| CN1201737C (en) | Application of cepharanthine in preparing medicine for resisting SARS virus | |
| CN1060344C (en) | Shumaining preparation for curing ischemic angiocardiopathy or cerebrovascular disease | |
| CN1861113A (en) | Application of Qishen Yiqi dripping pills for preparing medicine to inhibit degranulation of labrocyte | |
| CN1083721C (en) | Compound Chinese herb medicine for curing fibrosis of liver and hepatocirrhosis and its preparation method | |
| CN1096269C (en) | Medicinal composition for treating cardiovascular disease and its preparing process | |
| CN100411639C (en) | Use of compound red-rooted salvia drop pills in preparation of albumin leakage prohibiting drug | |
| CN1481806A (en) | Injection formulation of astragalus root saponin and its preparation mehod | |
| CN100372547C (en) | Use of compound red-rooted salvia drop pills in preparation of mass cell degranulation prohibiting drug | |
| CN100387236C (en) | Pharmacetutical for treating cardiovascular and cerebrovascular disease and its preparing process | |
| CN102247349A (en) | Purpose of salvianolic acid A on prevention and / or treatment of liver pathology caused by diabetes | |
| CN1701808A (en) | Emulsion of red sage root for injection and its preparation process | |
| CN108743654B (en) | A kind of traditional Chinese medicine composition for treating ischemic heart disease and its preparation method and application | |
| CN1872280A (en) | Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method | |
| CN1899352A (en) | Chinese medicine effective part composition for supplementing qi and recovering pulse | |
| CN1785212A (en) | Novel cinobufogenin freeze-drying powder injection, its prepn. method and quality control method | |
| CN1283310C (en) | Chinese medicinal preparation for treating coronarg heart disease arrhythmia and its manufacturing process | |
| CN100430073C (en) | Use of compound red-rooted salvia drop pills in preparation of leucocyte adherence prohibiting drug | |
| KR100213667B1 (en) | The composition showing antidiabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP03 | Change of name, title or address |